Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomine - Sanofi Oncology

Next Previous
X
Search
Drug Profile

Apomine - Sanofi Oncology

Alternative Names: APB-231-A2; SK&F 99085; SR-45023A; SR-9223i

Latest Information Update: 10 Sep 2018

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator
  • Developer Sanofi Oncology
  • Class Antineoplastics; Bisphosphonates; Osteoporosis therapies
  • Mechanism of Action Antioxidants; Apoptosis stimulants; Bone resorption factor inhibitors; Farnesoid X-activated receptor modulators; HMG-CoA reductase inhibitors; Osteoclast inhibitors; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis; Breast cancer; Cancer metastases; Hypercholesterolaemia; Malignant melanoma; Ovarian cancer; Postmenopausal osteoporosis; Prostate cancer; Solid tumours

Most Recent Events

  • 27 Aug 2018 Genzyme completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT00003822)
  • 27 Aug 2018 Genzyme completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT00004049)
  • 04 Feb 2008 Discontinued - Phase-I/II for Postmenopausal osteoporosis treatment in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top